RESUMEN
Apoptosis Signal-Regulating Kinase-1 (ASK1) is a known member of the Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) family and upon stimulation will activate the p38- and JNK-pathways leading to cardiac apoptosis, fibrosis, and hypertrophy. Using Structure-Based Drug Design (SBDD) in parallel with deconstruction of a published compound, a novel series of ASK1 inhibitors was optimized, which incorporated a saturated heterocycle proximal to the hinge-binding motif. This yielded a unique chemical series with excellent selectivity across the broader kinome, and desirable drug-like properties. The lead compound (10) is highly soluble and permeable, and exhibits a cellular EC50 = 24 nM and Kd < 1 nM. Of the 350 kinases tested, 10 has an IC50 ≤ 500 nM for only eight of them. This paper will describe the design hypotheses behind this series, key data points during the optimization phase, as well as a possible structural rationale for the kinome selectivity. Based on crystallographic data, the presence of an aliphatic cycle adjacent to the hinge-binder in the active site of the protein kinase showed up in <1% of the >5000 structures in the Protein Data Bank, potentially conferring the selectivity seen in this series.
Asunto(s)
MAP Quinasa Quinasa Quinasa 5/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/química , Animales , Sitios de Unión , Dominio Catalítico , Cristalografía por Rayos X , Diseño de Fármacos , Humanos , Imidazoles/química , Imidazoles/metabolismo , Imidazoles/uso terapéutico , Concentración 50 Inhibidora , MAP Quinasa Quinasa Quinasa 5/metabolismo , Ratones , Simulación de Dinámica Molecular , Daño por Reperfusión Miocárdica/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/metabolismo , Inhibidores de Proteínas Quinasas/uso terapéuticoRESUMEN
BACKGROUND & AIMS: Increasing evidence highlights dietary fructose as a major driver of non-alcoholic fatty liver disease (NAFLD) pathogenesis, the majority of which is cleared on first pass through the hepatic circulation by enzymatic phosphorylation to fructose-1-phosphate via the ketohexokinase (KHK) enzyme. Without a current approved therapy, disease management emphasises lifestyle interventions, but few patients adhere to such strategies. New targeted therapies are urgently required. METHODS: We have used a unique combination of human liver specimens, a murine dietary model of NAFLD and human multicellular co-culture systems to understand the hepatocellular consequences of fructose administration. We have also performed a detailed nuclear magnetic resonance-based metabolic tracing of the fate of isotopically labelled fructose upon administration to the human liver. RESULTS: Expression of KHK isoforms is found in multiple human hepatic cell types, although hepatocyte expression predominates. KHK knockout mice show a reduction in serum transaminase, reduced steatosis and altered fibrogenic response on an Amylin diet. Human co-cultures exposed to fructose exhibit steatosis and activation of lipogenic and fibrogenic gene expression, which were reduced by pharmacological inhibition of KHK activity. Analysis of human livers exposed to 13C-labelled fructose confirmed that steatosis, and associated effects, resulted from the accumulation of lipogenic precursors (such as glycerol) and enhanced glycolytic activity. All of these were dose-dependently reduced by administration of a KHK inhibitor. CONCLUSIONS: We have provided preclinical evidence using human livers to support the use of KHK inhibition to improve steatosis, fibrosis, and inflammation in the context of NAFLD. LAY SUMMARY: We have used a mouse model, human cells, and liver tissue to test how exposure to fructose can cause the liver to store excess fat and become damaged and scarred. We have then inhibited a key enzyme within the liver that is responsible for fructose metabolism. Our findings show that inhibition of fructose metabolism reduces liver injury and fibrosis in mouse and human livers and thus this may represent a potential route for treating patients with fatty liver disease in the future.
RESUMEN
The crystal structures of many tertiary alpha-ketoamides reveal an orthogonal arrangement of the two carbonyl groups. Based on the hypothesis that the alpha-ketoamide HIV attachment inhibitor BMS 806 (formally BMS378806, 26) might bind to its gp120 target via a similar conformation, we designed and synthesized a series of analogs in which the ketoamide group is replaced by an isosteric sulfonamide group. The most potent of these analogs, 14i, demonstrated antiviral potency comparable to 26 in the M33 pseudotyped antiviral assay. Flexible overlay calculations of a ketoamide inhibitor with a sulfonamide inhibitor revealed a single conformation of each that gave significantly better overlap of key pharmacophore features than other conformations and thus suggest a possible binding conformation for each class.
Asunto(s)
Fármacos Anti-VIH/síntesis química , VIH-1/efectos de los fármacos , Piperazinas/síntesis química , Fármacos Anti-VIH/química , Fármacos Anti-VIH/farmacología , Diseño de Fármacos , VIH-1/fisiología , Modelos Moleculares , Conformación Molecular , Piperazinas/química , Piperazinas/farmacología , Estereoisomerismo , Relación Estructura-Actividad , Internalización del Virus/efectos de los fármacos , Replicación Viral/efectos de los fármacosRESUMEN
[This corrects the article DOI: 10.1021/acsmedchemlett.6b00481.].
RESUMEN
Apoptosis signal-regulating kinase 1 (ASK1/MAP3K) is a mitogen-activated protein kinase family member shown to contribute to acute ischemia/reperfusion injury. Using structure-based drug design, deconstruction, and reoptimization of a known ASK1 inhibitor, a lead compound was identified. This compound displayed robust MAP3K pathway inhibition and reduction of infarct size in an isolated perfused heart model of cardiac injury.
RESUMEN
Anaplastic lymphoma kinase (ALK) is a promising new target for therapy of certain cancers such as anaplastic large-cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). We have identified a series of novel pyridones as kinase inhibitors of ALK by application of a stepwise process involving in vitro screening of a novel targeted library followed by iterative template modification based on medicinal chemistry insights and computational ranking of virtual libraries. Using this process, we discovered ALK-selective inhibitors with improved potency and selectivity. Herein the details of the design process and synthesis of these novel pyridones, along with their enzymatic and cell-based activity, are discussed.
Asunto(s)
Amidas/síntesis química , Antineoplásicos/síntesis química , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Piridonas/síntesis química , Amidas/química , Amidas/farmacología , Quinasa de Linfoma Anaplásico , Animales , Antineoplásicos/química , Antineoplásicos/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Técnicas Químicas Combinatorias , Bases de Datos Factuales , Diseño de Fármacos , Humanos , Ratones , Modelos Moleculares , Piridonas/química , Piridonas/farmacología , Proteínas Tirosina Quinasas Receptoras , Relación Estructura-ActividadRESUMEN
A series of bivalent ligands of varying length were synthesized to inhibit the receptor-binding process of cholera toxin. Competitive surface receptor binding assays showed that significant potency gains relative to the constituent monovalent ligands were achieved independently from the ability of the extended bivalent ligands to span binding sites within the toxin pentamer. Several models that could account for the unexpected improvement in IC(50) values are examined, taking into account crystallographic analysis of each ligand in complex with the toxin pentamer. Evidence is presented that steric blocking at the receptor binding surface may play a role. The results of our study suggest that the use of relatively short, "nonspanning" bivalent ligands, or monovalent ligands of similar topology and bulk may be an effective way of blocking the interaction of multimeric proteins with their cell surface receptors.
Asunto(s)
Amidas/química , Amidas/farmacología , Toxina del Cólera/antagonistas & inhibidores , Toxina del Cólera/metabolismo , Nitrofenilgalactósidos/química , Nitrofenilgalactósidos/farmacología , Amidas/síntesis química , Secuencia de Aminoácidos , Unión Competitiva , Cristalografía por Rayos X , Concentración 50 Inhibidora , Ligandos , Datos de Secuencia Molecular , Estructura Molecular , Nitrofenilgalactósidos/síntesis química , Piperazinas/síntesis química , Piperazinas/química , Piperazinas/farmacología , Unión Proteica , Receptores de Superficie Celular/antagonistas & inhibidores , Receptores de Superficie Celular/metabolismoRESUMEN
The action of cholera toxin and E. coli heat-labile enterotoxin can be inhibited by blocking their binding to the cell-surface receptor GM1. We have used anchor-based design to create 15 receptor binding inhibitors that contain the previously characterized inhibitor MNPG as a substructure. In ELISA assays, all 15 compounds exhibited increased potency relative to MNPG. Binding affinities for two compounds, each containing a morpholine ring linked to MNPG via a hydrophobic tail, were characterized by pulsed ultrafiltration (PUF) and isothermal titration calorimetry (ITC). Crystal structures for these compounds bound to toxin B pentamer revealed a conserved binding mode for the MNPG moiety, with multiple binding modes adopted by the attached morpholine derivatives. The observed binding interactions can be exploited in the design of improved toxin binding inhibitors.
Asunto(s)
Toxinas Bacterianas/química , Toxina del Cólera/química , Enterotoxinas/química , Proteínas de Escherichia coli , Galactosa/química , Receptores de Superficie Celular/antagonistas & inhibidores , Receptores de Superficie Celular/química , Toxinas Bacterianas/metabolismo , Unión Competitiva , Toxina del Cólera/metabolismo , Cristalografía , Diseño de Fármacos , Enterotoxinas/metabolismo , Ensayo de Inmunoadsorción Enzimática , Escherichia coli/metabolismo , Galactosa/análogos & derivados , Galactosa/metabolismo , Modelos Moleculares , Conformación Proteica , Receptores de Superficie Celular/metabolismo , Relación Estructura-ActividadRESUMEN
[reaction: see text] Efficient syntheses of guanidine-bridged poly(ethylene glycol) linkers of various lengths in fully protected form are reported for both solution- and solid-phase protocols. The application of such linkers in the construction of water-soluble and high-affinity multivalent ligands against cholera toxin is demonstrated. Synthetic intermediates for multivalent ligands as large as 20 kDa in molecular weight have been assembled using presynthesized linkers. The final ligands are highly water-soluble, thus enabling proper biophysical characterization.
Asunto(s)
Guanidinas/química , Polietilenglicoles/síntesis química , Soluciones/química , Agua/química , Secuencia de Carbohidratos , Toxina del Cólera/antagonistas & inhibidores , Toxina del Cólera/química , Guanidinas/síntesis química , Guanidinas/farmacología , Ligandos , Datos de Secuencia Molecular , Peso Molecular , Polietilenglicoles/química , Polietilenglicoles/farmacologíaRESUMEN
Previously disclosed HIV (human immunodeficiency virus) attachment inhibitors, exemplified by BMS 806 (formally BMS378806, 1), are characterized by a substituted indole or azaindole ring linked to a benzoylpiperazine via a ketoamide or sulfonamide group. In the present report, we describe the discovery of a novel series of potent HIV entry inhibitors in which the indole or azaindole ring of previous inhibitors is replaced by a heterobiaryl group. Several of these analogues exhibited IC(50) values of less than 5 nM in a pseudotyped antiviral assay, and compound 13k was demonstrated to exhibit potency and selectivity similar to those of 1 against a panel of clinical viral isolates. Moreover, current structure-activity relationship studies of these novel biaryl gp120 inhibitors revealed that around the biaryl, a fine crevice might exist in the gp120 binding site. Taken in sum, these data reveal a hitherto unsuspected flexibility in the structure-activity relationships for these inhibitors and suggest new avenues for exploration and gp120 inhibitor design.
Asunto(s)
Fármacos Anti-VIH/química , Fármacos Anti-VIH/farmacología , VIH/efectos de los fármacos , VIH/fisiología , Piperazinas/química , Piperazinas/farmacología , Internalización del Virus/efectos de los fármacos , Animales , Fármacos Anti-VIH/síntesis química , Descubrimiento de Drogas , Humanos , Indoles/química , Concentración 50 Inhibidora , Piperazinas/síntesis química , Relación Estructura-Actividad , Replicación Viral/efectos de los fármacosRESUMEN
With the aim of developing high-affinity mono and multivalent antagonists of cholera toxin (CT) and Escherichia coli heat-labile enterotoxin (LT) we are using the galactose portion of the natural receptor ganglioside GM1 as an anchoring fragment in structure-based inhibitor design efforts. In order to establish a better structure-activity relationship for guiding these studies, we designed and prepared a small focused library of twenty 3,5-substituted phenylgalactosides based on two previous leads. The compounds were tested for their ability to block CTB(5) binding to immobilized ganglioside receptor and compared to the two previous leads. The crystal structures of the most promising compounds bound to either CTB(5) or LTB(5) were then determined in order to understand the basis for affinity differences. The most potent new compound yielded a six-fold improvement over our benchmark lead m-nitrophenyl-alpha-d-galactopyranoside (MNPG), and a two-fold improvement in IC(50) over a newer MNPG derivative. These results support the notion that the m-nitrophenyl moiety of MNPG and its derivatives is an important element to retain in future optimization efforts. Additionally, a consensus binding-pocket for the alkylmorpholine or piperazine moiety present in all of the designed antagonists was established as an important area of the GM1 binding site to target in future work.
Asunto(s)
Toxina del Cólera/antagonistas & inhibidores , Diseño de Fármacos , Galactósidos/síntesis química , Animales , Sitios de Unión , Cristalografía por Rayos X , Galactósidos/química , Galactósidos/farmacología , Humanos , Concentración 50 Inhibidora , Modelos Moleculares , Estructura Molecular , Receptores de Superficie Celular/antagonistas & inhibidores , Relación Estructura-ActividadRESUMEN
Multivalent ligand design constitutes an attractive avenue to the inhibition of receptor recognition and other biological events mediated by oligomeric proteins with multiple binding sites. One example is the design of multivalent receptor blockers targeting members of the AB(5) bacterial toxin family. We report here the synthesis and characterization of a pentavalent inhibitor for cholera toxin and Escherichia coli heat-labile enterotoxin. This inhibitor is an advance over the symmetric pentacyclen-derived inhibitor described in our earlier work in that it presents five copies of m-nitrophenyl-alpha-D-galactoside (MNPG) rather than five copies of beta-D-galactose. The approximately 100-fold higher single-site affinity of MNPG for the toxin receptor binding site relative to galactose is found to yield a proportionate increase in the affinity and IC50 measured for the respective pentavalent constructs. We show by dynamic light scattering that inhibition of receptor binding by the pentavalent inhibitor is due to 1:1 inhibitor:toxin association rather than to inhibitor-mediated aggregation. This 1:1 association is in complete agreement with a 1.46 A resolution crystal structure of the pentavalent inhibitor:toxin complex, which shows that the favorable single-site binding interactions of MNPG are retained by the five arms of the 5256 Da pentavalent MNPG-based inhibitor and that the initial segment of the linking groups interacts with the surface of the toxin B pentamer.
Asunto(s)
Toxinas Bacterianas/antagonistas & inhibidores , Toxina del Cólera/antagonistas & inhibidores , Enterotoxinas/antagonistas & inhibidores , Proteínas de Escherichia coli , Gangliósido G(M1)/antagonistas & inhibidores , Nitrofenilgalactósidos/química , Receptores de Superficie Celular/antagonistas & inhibidores , Receptores Inmunológicos/antagonistas & inhibidores , Toxinas Bacterianas/química , Toxinas Bacterianas/metabolismo , Toxina del Cólera/química , Toxina del Cólera/metabolismo , Cristalografía por Rayos X , Enterotoxinas/química , Enterotoxinas/metabolismo , Escherichia coli/metabolismo , Gangliósido G(M1)/química , Gangliósido G(M1)/metabolismo , Cinética , Ligandos , Luz , Modelos Moleculares , Nitrofenilgalactósidos/síntesis química , Nitrofenilgalactósidos/metabolismo , Receptores de Superficie Celular/química , Receptores de Superficie Celular/metabolismo , Receptores Inmunológicos/química , Receptores Inmunológicos/metabolismo , Dispersión de RadiaciónRESUMEN
Structural biology studies on cholera toxin and the closely related heat-labile enterotoxin from enterotoxigenic Escherichia coli over the past decade have shed light on the mechanism of toxin action at molecular and atomic levels. Also, components of the extracellular protein secretion apparatus that translocate the toxins across the outer membrane are being investigated. At the same time, structure-based design has led to various classes of compounds targeting different toxin sites, including highly potent multivalent inhibitors that block the toxin receptor-binding process.